Skip to main content
SYNTARA LIMITED logo

SYNTARA LIMITED — Investor Relations & Filings

Ticker · SNT ISIN · AU0000312480 LEI · 52990054L6XWT345FW20 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,620 across all filing types
Latest filing 2010-12-13 Major Shareholding Noti…
Country AU Australia
Listing ASX SNT

About SYNTARA LIMITED

https://syntaratx.com.au/

Syntara Limited is a clinical-stage drug development company focused on the discovery and development of novel small molecule therapeutics for inflammatory and fibrotic diseases. The company specializes in the inhibition of amine oxidase enzymes, including lysyl oxidase (LOX) and semicarbazide-sensitive amine oxidase (SSAO). Its primary clinical focus is on hematological malignancies and multi-organ fibrosis. The lead drug candidate, PXS-5505, is a pan-LOX inhibitor currently being evaluated for the treatment of myelofibrosis. Additionally, the company develops treatments for skin scarring, pulmonary fibrosis, and neurodegenerative conditions. Syntara leverages its proprietary drug discovery platform to address significant unmet medical needs through targeted enzymatic inhibition, aiming to modify disease progression in complex pathological environments.

Recent filings

Filing Released Lang Actions
Ceasing to be a substantial holder 3 pages ?Kb
Major Shareholding Notification Classification · 100% confidence The document is titled 'Substantial Shareholder Notice' and references Form 605 under the Corporations Act 2001 (Cth), which is a regulatory form used to notify changes in substantial shareholdings. It details the cessation of a substantial holding in Pharmaxis Limited, including dates, share transactions, and relevant legal references. This type of filing is a notification of changes in significant share ownership levels, which aligns with the definition of 'Major Shareholding Notification' (Code: MRQ). The document is not a financial report, earnings release, or management report, but a formal regulatory notice about shareholding changes.
2010-12-13 English
Bronchitol Recommended for Approval by Australian Advisory C 2 pages ?Kb
Regulatory Filings Classification · 95% confidence The document is a media release dated 13 December 2010 from Pharmaxis Ltd announcing that the Australian Advisory Committee on Prescription Medicines (ACPM) has recommended approval of their drug Bronchitol for marketing in Australia. The content focuses on regulatory approval progress, clinical trial background, and company information. There are no financial statements, earnings data, or detailed financial analysis. The document is a public announcement about a regulatory milestone rather than a financial report or detailed investor presentation. It does not fit into categories like Annual Report, Earnings Release, or Investor Presentation. It is a regulatory announcement about drug approval recommendation, which aligns best with Regulatory Filings (RNS) as a general category for regulatory and compliance announcements that do not fit other specific categories.
2010-12-12 English
Phase II Trial of ASM8 in Asthma Commences 3 pages ?Kb
Regulatory Filings Classification · 90% confidence The document is a media release announcing the commencement of a Phase II clinical trial for a new asthma drug, ASM8. It provides details about the trial design, endpoints, and company background. There are no financial statements, regulatory filings, or detailed financial data. The document is a public announcement about a clinical trial start, which is typical for a press release or media release. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is not a report publication announcement since it does not mention the release of a report. The content is primarily informational about a clinical trial and company product development, which is outside the scope of the defined filing categories. Therefore, the best fit is Regulatory Filings (RNS) as a general announcement that does not fit other categories.
2010-12-06 English
Appendix 3B - Exercise of Employee Options 11 pages ?Kb
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3B New issue announcement' and contains detailed information about the issuance of new securities, including the class of securities, number issued, terms, exercise prices, and dates. It references ASX rules and includes a quotation agreement section. The content is focused on the announcement and application for quotation of additional securities, which aligns with capital raising or share issuance activities. There are no financial statements or management discussion, nor is it a report or transcript. The document is a formal announcement related to new share issues and capital changes. Therefore, the appropriate classification is 'Share Issue/Capital Change' (SHA). The document length and detail support a high confidence score.
2010-11-29 English
Appendix 3B - Exercise of Employee Options 11 pages ?Kb
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3B New issue announcement' and references ASX rules and sections of the Corporations Act. It details the issuance of fully paid ordinary shares upon exercise of options under the Pharmaxis Ltd Employee Option Plan, including the number of securities issued, their class, exercise prices, expiry dates, and other terms. The document also includes a quotation agreement with the ASX and warranties related to the securities issuance. This type of document is a formal announcement of a new share issue and application for quotation of additional securities on the ASX, consistent with Appendix 3B filings used in Australian markets for capital raising and securities issuance announcements. It is not a full financial report, earnings release, or management discussion, but a regulatory announcement about capital changes. Therefore, the appropriate classification is 'Share Issue/Capital Change' (SHA). The document length (14,689 characters) and detailed content confirm it is the announcement itself, not just a brief notice or report publication announcement.
2010-11-24 English
Change of Director`s Interest Notice 2 pages ?Kb
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in a director's relevant interests in securities, including the exercise of options and acquisition of shares. The content is focused on insider share transactions by a company director, reporting the number of securities held before and after the change, the nature of the transaction, and the consideration paid. This matches the definition of 'Director's Dealing' filings, which report personal share transactions by company directors and executives (insider trades). The document length is 3333 characters, which is consistent with a detailed notice rather than a brief announcement or a full financial report. Therefore, the correct classification is DIRS (Director's Dealing).
2010-11-24 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.